• Alto Neuroscience’s third-quarter 2026 net loss widened 77% year over year to $25.12 million.
• Research and development expenses rose 73% to $18.16 million, primarily driven by ALTO-207 PACE program costs.
• Cash, cash equivalents and restricted cash totaled $319.84 million at September 30, 2026, expected to fund planned operations through 2030.
• PACE-1 topline data remain expected in the second half of 2027.
• ALTO-207 Phase 3 adjunctive and monotherapy trials are planned for early and second-half 2027, respectively, pending FDA alignment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alto Neuroscience Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202611101605BIZWIRE_USPR_____20261110_BW590023) on November 10, 2026, and is solely responsible for the information contained therein.